Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections

Area of Science:

• Microbiology
• Infectious Diseases
• Bacteriology

Background:

• Chronic urinary and urogenital infections often involve multidrug-resistant bacteria.
• Phage therapy (PT) presents an alternative treatment strategy for bacterial infections.
• Assessing immune responses to PT is crucial for understanding its efficacy and safety.

Purpose of the Study:

• To evaluate the efficacy and immunogenicity of phage therapy in patients with chronic urogenital multidrug-resistant bacterial infections.
• To determine the impact of intravesical and intravaginal phage administration on serum antibody levels.
• To explore the potential of PT as a viable therapeutic option for urogenital infections.

Main Methods:

• Patients received phage therapy via intravesical or intravesical and intravaginal administration.
• Serum samples were collected to measure antibody responses against administered phages.
• Therapeutic outcomes were assessed in patients undergoing phage therapy.

Main Results:

• A single course of PT did not significantly increase serum antibody levels.
• A second cycle of PT led to a significant, yet low, increase in antibody levels.
• Good therapeutic results were observed in some patients, despite low antibody responses.

Conclusions:

• Phage therapy may be an efficient treatment for urogenital infections caused by multidrug-resistant bacteria.
• The low immunogenicity observed suggests PT could be a safe therapeutic approach.
• These findings support PT as a reliable model for future clinical trials in urogenital infections.